Literature DB >> 19456250

The effect of DYS-14 copy number variations on extracellular fetal DNA quantification in maternal circulation.

Ilona Hromadnikova1, Martina Benesova, Lenka Zejskova, Jana Stehnova, Jindrich Doucha, Petr Sedlacek, Klara Dlouha, Ladislav Krofta.   

Abstract

The aims of our research involved to investigate DYS-14 copy number variations in healthy males, to quantify extracellular DNA in maternal circulation in normal versus complicated pregnancies, and to study variations in the DYS-14 copy number in extracellular male fetal DNA. Fifty-five healthy males, 43 uncomplicated male singleton pregnancies (23 sampled at the 16th week and 20 sampled at the 36th week), and 15 pregnancies with placental insufficiency (PI)-related complications (mean 34.1 weeks) were analyzed using real-time PCR with DYS-14 sequence, sex determining region Y (SRY), and beta-globin (GLO) genes used as markers. Increased levels of extracellular DNA were detected in PI-related complications relative to gestational age-matched controls (SRY, p < 0.001; DYS-14, p = 0.007; GLO, p < 0.001). When the mean + 2SD (standard deviation) of controls was used as a cutoff, SRY, DYS-14, and GLO achieved 91.7%, 68.8%, and 94.4% accuracy, respectively, for differentiation between normal and complicated pregnancies. Considerable variations in the DYS-14 copy number in healthy males (mean 52.6) and extracellular DNA were found. A lower DYS-14 copy number was observed in PI-related complications (mean 83.5) compared to uncomplicated pregnancies (16th week: mean 114.2, p = 0.02; 36th week: mean 142.8, p = 0.04). The DYS-14 copy number was higher in extracellular DNA throughout gestation relative to healthy males. We concluded that, regarding interindividual copy number variations, the DYS-14 sequence is not an optimal marker for extracellular fetal DNA quantification for differentiation between normal and complicated pregnancies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19456250     DOI: 10.1089/dna.2009.0855

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  6 in total

Review 1.  Extracellular nucleic acids in maternal circulation as potential biomarkers for placental insufficiency.

Authors:  Ilona Hromadnikova
Journal:  DNA Cell Biol       Date:  2012-02-24       Impact factor: 3.311

2.  Detection and quantification of male-specific fetal DNA in the serum of pregnant cynomolgus monkeys (Macaca fascicularis).

Authors:  Lubna Yasmin; Jun-Ichiro Takano; Yasushi Nagai; Junko Otsuki; Tadashi Sankai
Journal:  Comp Med       Date:  2015-02       Impact factor: 0.982

3.  The occurrence of fetal microchimeric cells in endometrial tissues is a very common phenomenon in benign uterine disorders, and the lower prevalence of fetal microchimerism is associated with better uterine cancer prognoses.

Authors:  Ilona Hromadnikova; Katerina Kotlabova; Petra Pirkova; Pavla Libalova; Zdenka Vernerova; Bohuslav Svoboda; Eduard Kucera
Journal:  DNA Cell Biol       Date:  2013-11-27       Impact factor: 3.311

4.  First trimester screening of circulating C19MC microRNAs can predict subsequent onset of gestational hypertension.

Authors:  Ilona Hromadnikova; Katerina Kotlabova; Lucie Hympanova; Jindrich Doucha; Ladislav Krofta
Journal:  PLoS One       Date:  2014-12-15       Impact factor: 3.240

Review 5.  Do miRNAs Play a Role in Fetal Growth Restriction? A Fresh Look to a Busy Corner.

Authors:  Benito Chiofalo; Antonio Simone Laganà; Alberto Vaiarelli; Valentina Lucia La Rosa; Diego Rossetti; Vittorio Palmara; Gaetano Valenti; Agnese Maria Chiara Rapisarda; Roberta Granese; Fabrizio Sapia; Onofrio Triolo; Salvatore Giovanni Vitale
Journal:  Biomed Res Int       Date:  2017-03-29       Impact factor: 3.411

6.  Circulating C19MC microRNAs in preeclampsia, gestational hypertension, and fetal growth restriction.

Authors:  Ilona Hromadnikova; Katerina Kotlabova; Marketa Ondrackova; Andrea Kestlerova; Veronika Novotna; Lucie Hympanova; Jindrich Doucha; Ladislav Krofta
Journal:  Mediators Inflamm       Date:  2013-11-14       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.